- Home
- TNXP vs OPFI Comparison
TNXP vs OPFI Comparison
Compare TNXP & OPFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- OPFI
- Stock Information
- Founded
- TNXP 2007
- OPFI 2009
- Country
- TNXP United States
- OPFI United States
- Employees
- TNXP N/A
- OPFI N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- OPFI Finance: Consumer Services
- Sector
- TNXP Health Care
- OPFI Finance
- Exchange
- TNXP Nasdaq
- OPFI Nasdaq
- Market Cap
- TNXP 335.6M
- OPFI 343.1M
- IPO Year
- TNXP N/A
- OPFI N/A
- Fundamental
- Price
- TNXP $22.41
- OPFI $10.02
- Analyst Decision
- TNXP Buy
- OPFI Buy
- Analyst Count
- TNXP 1
- OPFI 2
- Target Price
- TNXP $70.00
- OPFI $11.75
- AVG Volume (30 Days)
- TNXP 1.1M
- OPFI 967.8K
- Earning Date
- TNXP 11-11-2025
- OPFI 10-29-2025
- Dividend Yield
- TNXP N/A
- OPFI 9.96%
- EPS Growth
- TNXP N/A
- OPFI N/A
- EPS
- TNXP N/A
- OPFI N/A
- Revenue
- TNXP $9,831,000.00
- OPFI $320,831,000.00
- Revenue This Year
- TNXP $14.79
- OPFI $118.17
- Revenue Next Year
- TNXP $933.49
- OPFI $11.29
- P/E Ratio
- TNXP N/A
- OPFI N/A
- Revenue Growth
- TNXP N/A
- OPFI 31.26
- 52 Week Low
- TNXP $6.76
- OPFI $4.41
- 52 Week High
- TNXP $130.00
- OPFI $17.73
- Technical
- Relative Strength Index (RSI)
- TNXP 30.44
- OPFI 39.58
- Support Level
- TNXP $23.60
- OPFI $10.05
- Resistance Level
- TNXP $29.19
- OPFI $12.45
- Average True Range (ATR)
- TNXP 1.63
- OPFI 0.57
- MACD
- TNXP 0.12
- OPFI -0.18
- Stochastic Oscillator
- TNXP 5.31
- OPFI 7.50
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.